Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11–23.
   PubMed Web of Science ®Google Scholar
• Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997;14:439–449.
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–1134.
   PubMed Web of Science ®Google Scholar
• Palmer RH, Vernersson E, Grabbe C, et al. Anaplastic lymphoma kinase: signaling in development and disease. Biochem J. 2009;420:345–361.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res. 2013;68:68–94.
   PubMed Web of Science ®Google Scholar
• Lee CC, Jia Y, Li N, et al. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J. 2010;430:425–437.
   PubMed Web of Science ®Google Scholar
• Bossi RT, Saccardo MB, Ardini E, et al. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry. 2010;49:6813–6825.
   PubMed Web of Science ®Google Scholar
• Stoica GE, Kuo A, Powers C, et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem. 2002;277:35990–35998.
   PubMed Web of Science ®Google Scholar
• Perez-Pinera P, Zhang W, Chang Y, et al. Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. J Biol Chem. 2007;282:28683–28690.
   PubMed Web of Science ®Google Scholar
• Reshetnyak AV, Murray PB, Shi X, et al. Augmentor alpha and _ (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: hierarchy and specificity of ligand-receptor interactions. Proc Natl Acad Sci USA. 2015;112:15862–15867.
   PubMed Web of Science ®Google Scholar
• Lemke G. Adopting ALK and LTK. Proc Natl Acad Sci USA. 2015;112:15783–15784.
   PubMed Web of Science ®Google Scholar
• Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1995;267:316–317.
   PubMed Web of Science ®Google Scholar
• Shiota M, Fujimoto J, Semba T, et al. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene. 1994;9:1567–1574.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–566.
   PubMed Web of Science ®Google Scholar
• Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res. 2015;21(10):2227–2235.
   PubMed Web of Science ®Google Scholar
• Chiarle R, Martinengo C, Mastini C, et al. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med. 2008;14:676–680.
   PubMed Web of Science ®Google Scholar
• Toyokawa G, Seto T. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance. Respir Investig. 2014;52:330–338.
   PubMedGoogle Scholar
• Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4- ALK-positive lung cancer. Proc Natl Acad Sci USA. 2008;105(50):19893–19897.
   PubMed Web of Science ®Google Scholar
• Marino-Enriquez A, Dal Cin P. ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. Cancer Genet. 2013;206:357–373.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med. 2010;363:1693–1703.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011–1019.
   PubMed Web of Science ®Google Scholar
• Kim DW, Ahn MJ, Shi Y, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) abstract. J Clin Oncol. 2012;30(Suppl).
   Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31:1105–1111.
   PubMed Web of Science ®Google Scholar
• Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33(17):1881–1888.
   PubMed Web of Science ®Google Scholar
• Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):e443–5.
   PubMed Web of Science ®Google Scholar
• Metro G, Lunardi G, Floridi P, et al. CSF concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment. J Thorac Oncol. 2015;10(5):e26–7.
   PubMed Web of Science ®Google Scholar
• Tang SC, Nguyen LN, Sparidans RW, et al. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the Pglycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014;134:1484–1494.
   PubMed Web of Science ®Google Scholar
• Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4:662–673.
   PubMed Web of Science ®Google Scholar
• Kim DW, Mehra R, Tan DS, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17(4):452–463.
   PubMed Web of Science ®Google Scholar
• Mok T, Spigel D, Felip E, et al. ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol. 2015;33:8059-8059. Suppl. abstract.
   Google Scholar
• Felip E, Orlov S, Park K, et al. Phase 2 study of ceritinib in alki-naive patients (pts) with alk-rearranged (alk +) non-small cell lung cancer (nsclc): whole body responses in the overall pt group and in pts with baseline brain metastases (bm). Ann Oncol 2016;27(6):416-454.
   Google Scholar
• Scagliotti G, Kim TM, Crinò L et al. Ceritinib versus chemotherapy in patients with advanced ALK+ NSCLC previously treated with chemotherapy and crizotinib: results from the confirmatory phase III ASCEND-5 study. ESMO 2016; Oral LBA42.
   Google Scholar
• Soria JC, Tan DS, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALKrearranged non-small cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917–929.
   PubMed Web of Science ®Google Scholar
• Cho BC, Kim DW, Bearz A, et al. ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol. 2017;12(9):1357–1367.
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119–1128.
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Asoh K, Furuichi N, et al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (ch5424802). Bioorg Med Chem. 2012;20:1271–1280.
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Tsukaguchi T, Hiroshima S, et al. Ch5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011;19:679–690.
   PubMed Web of Science ®Google Scholar
• Tamura T, Kiura K, Seto T, et al. Three-year follow-up of an alectinib phase I/II study in ALK-positive non-small cell lung cancer: AF-001JP. J Clin Oncol. 35:1515–1521.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17(2):234–242.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Gadgeel SM, Ou S, et al. MA07.02 Updated efficacy and safety data from the phase 2 NP28761 study of alectinib in ALK-positive non-small cell lung cancer. J Thorac Oncol. 2017;12(1):S378.
   Google Scholar
• Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK- rearranged non-small cell lung cancer: a Phase II global study. J Clin Oncol. 2016;34:661–668.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Ou SI, Shaw AT, et al. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small cell lung cancer: comparison of RECIST 1.1 and RANO-HGG criteria. Eur J Cancer. 2017;82:27–33.
   PubMed Web of Science ®Google Scholar
• Novello S, Mazieres J, Oh I-J et al. Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small cell lung cancer (NSCLC). Ann Oncol 2017;28(5):639-639.
   Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small cell lung cancer. N Engl J Med. 2017;377(9):829–838.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Peters S, Mok T, et al. Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK+ NSCLC. J Clin Oncol. 2018;36(Suppl): abstract 9043
   PubMedGoogle Scholar
• Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017;390(10089):29–39.
   PubMed Web of Science ®Google Scholar
• Takiguchi Y, Hida T, Nokihara H, et al. Updated efficacy and safety of the J-ALEX study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC). J Clin Oncol. 2017;35(abstract):9064.
   Google Scholar
• Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6:1118–1133.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013;31(31):3987–3996.
   PubMed Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra117.
   Web of Science ®Google Scholar
• Zuccotto F, Ardini E, Casale E, et al. Through the “gatekeeper door”: exploiting the active kinase conformation. J Med Chem. 2010;53:2681–2694.
   PubMed Web of Science ®Google Scholar
• Azam M, Seeliger MA, Gray NS, et al. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol. 2008;15:1109–1118.
   PubMed Web of Science ®Google Scholar
• Katayama R, Friboulet L, Koike S, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res. 2014;20(22):5686–5696.
   PubMed Web of Science ®Google Scholar
• Rc D, Ab P, Dl A, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18(5):1472–1482.
   PubMed Web of Science ®Google Scholar
• Ceccon M, Mologni L, Bisson W, et al. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Mol Cancer Res. 2013;11(2):122–132.
   PubMed Web of Science ®Google Scholar
• Toyokawa G, Hirai F, Inamasu E, et al. Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib. J Thorac Oncol. 2014;9(12):e86–7.
   PubMed Web of Science ®Google Scholar
• Fontana D, Ceccon M, Gambacorti-Passerini C, et al. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. Cancer Med. 2015;4:953–965.
   PubMed Web of Science ®Google Scholar
• Toyokawa G, Inamasu E, Shimamatsu S, et al. Identification of a novel ALKG1123S mutation in a patient with ALK-rearranged non-small cell lung cancer exhibiting resistance to ceritinib. J Thorac Oncol. 2015;10:e55–7.
   PubMed Web of Science ®Google Scholar
• Tchekmedyian N, Ali SM, Miller VA, et al. Acquired ALK l1152r mutation confers resistance to ceritinib and predicts response to alectinib. J Thorac Oncol. 2016;11:e87–8.
   PubMed Web of Science ®Google Scholar
• Ou SHI, Azada M, Hsiang DJ, et al. Next-generation sequencing reveals a novel NSCLCALK f1174v mutation and confirms ALKG1202R mutation confers high-level resistance to alectinib (ch5424802/ro5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol. 2014;9(4):549–553.
   PubMed Web of Science ®Google Scholar
• Tan DSW, Kim DW, Thomas M, et al. Genetic landscape of ALK+ non-small cell lung cancer (NSCLC) patients (pts) and response to ceritinib in ASCEND-1. J Clin Oncol. 2016;34(15_Suppl).
   Google Scholar
• Toyokawa G, Takashi S, Mitsuhiro T, et al. Crisotininb can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor? J Thorac Oncol. 2014;9(3):e27–8.
   PubMed Web of Science ®Google Scholar
• Dong X, Fernandez-Salas E, Li E, et al. Elucidation of resistance mechanisms to second-generation ALK inhibitors alectinib and ceritinib in non-small cell lung cancer cells. Neoplasia. 2016;18(3):162–171.
   PubMed Web of Science ®Google Scholar
• Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014;346(6216):1480–1486.
   PubMed Web of Science ®Google Scholar
• Huang WS, Liu S, Zou D, et al. Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase. J Med Chem. 2016;59:4948–4964.
   PubMed Web of Science ®Google Scholar
• Staff N. FDA grants brigatinib accelerated approval for metastatic non-small cell lung cancer. In: FDA grants brigatinib accelerated approval for metastatic non-small cell lung cancer. Vol. 2017.Rockville, MD, USA: National Cancer Institute; 2017. Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm555841.htm
   Google Scholar
• Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(12):1683–1696.
   PubMed Web of Science ®Google Scholar
• Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35:2490–2498.
   PubMed Web of Science ®Google Scholar
• Lin JJ, Zhu VW, Schoenfeld AJ, et al. Brigatinib in patients with alectinib-refractory ALK-positive NSCLC. J Thorac Oncol. 2018;13(10):1530-1538.
   Web of Science ®Google Scholar
• Zhang S, Anjum R, Squillace R, et al. The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models. Clin Cancer Res. 2016;22(22):5527–5538.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590–1599.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou S-HI, Felip E, et al. Efficacy and safety of lorlatinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): a phase I/II study. J Clin Oncol. 2017;35(abstract):9006.
   Google Scholar
• Solomon B, Shaw A, Ou S, et al. Phase 2 study of lorlatinib in patients with advanced ALK+/ROS1+ non-small cell lung cancer. J Thorac Oncol. 2017;12(11):S1756.
   Google Scholar
• Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med. 2016;374:54–61.
   PubMed Web of Science ®Google Scholar
• Menichincheri M, Ardini E, Magnaghi P, et al. Discovery of entrectinib: a new 3-aminoindazole as a potent Anaplastic Lymphoma Kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor. J Med Chem. 2016;59:3392–3408.
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Ou SI, et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7:400–409.
   PubMed Web of Science ®Google Scholar
• Horn L, Infante JR, Reckamp KL, et al. Ensartinib (X-396) in ALK-positive non-small cell lung cancer: results from a first-in-human phase I/II, multicenter study. Clin Cancer Res. 2018 Mar 21. DOI:10.1158/1078-0432. [ CCR-17-2398].
   PubMed Web of Science ®Google Scholar
• Arkenau H, Sachdev J, Mita M, et al. Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer. J Clin Oncol. 2015;33(abstract):8063.
   Google Scholar
• Cheng M, Quail MR, Gingrich DE, et al. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2012;11(3):670–679.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wu J, Wang A, et al. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-met hoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC. Eur J Med Chem. 2017;139:674–697.
   PubMed Web of Science ®Google Scholar
• Ota K, Azuma K, Kawahara A, et al. Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res. 2015;21:4014–4021.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Lee SH, Ramalingam SS, et al. Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: phase 1b results from JAVELIN Lung 101. J Clin Oncol. 2018;36:Suppl. abstract 9008
   Google Scholar
• Kim DW, Gadgeel SM, Gettinger SN, et al. Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC). J Clin Oncol. 2018;36:Suppl. abstract 9009
   Google Scholar
• Dr S, Reynolds C, Waterhouse D, et al. Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation - positive advanced non-small cell lung cancer (CheckMate 370). J Thorac Oncol. 2018;13(5):682–688.
   PubMed Web of Science ®Google Scholar
• Khoja L, Day D, Wei-Wu Chen T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol. 2017;28(10):2377–2385.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Shaw AT, Sequist LV, et al. Egfr mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22:4585–4593.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Tan DSW, De Pas T, et al. Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib. Clin Cancer Res. 2015;21(12):2745–2752.
   PubMed Web of Science ®Google Scholar
• Ito K, Hataji O, Kobayashi H, et al. Sequential therapy with crizotinib and alectinib in ALK-rearranged non-small cell lung cancer - a multicenter retrospective study. J Thorac Oncol. 2017;12(2):390–396.
   PubMed Web of Science ®Google Scholar
• Gouji T, Takashi S, Mitsuhiro T, et al. Crizotinib can overcome acquired resistance to ch5424802: is amplification of the met gene a key factor? J Thorac Oncol. 2014;9:e27–e28.
   PubMed Web of Science ®Google Scholar
• Cha YJ, Cho BC, Kim HR, et al. A case of ALK-rearranged adenocarcinoma with small cell carcinoma-like transformation and resistance to crizotinib. J Thorac Oncol. 2016;11:e55–e58.
   PubMed Web of Science ®Google Scholar
• Zhu YC, Liao XH, Wang WX, et al. Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small cell lung cancer: a case report. OncoTargets Ther. 2017;10:3187–3192.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Ikushima S, Ono R, et al. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib. Jpn J Clin Oncol. 2016;46:170–173.
   PubMed Web of Science ®Google Scholar
• Fujita S, Masago K, Katakami N, et al. Transformation to sclc after treatment with the ALK inhibitor alectinib. J Thorac Oncol. 2016;11:e67–e72.
   PubMed Web of Science ®Google Scholar
• Takegawa N, Hayashi H, Iizuka N, et al. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib. Ann Oncol. 2016;27:953–955.
   PubMed Web of Science ®Google Scholar
• Levacq D, D’Haene N, de Wind R, et al. Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: a new mechanism of resistance to ALK inhibitors. Lung Cancer. 2016;102:38–41.
   PubMed Web of Science ®Google Scholar
• Hida T, Seto T, Horinouchi H, et al. Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9. Cancer Sci. 2018;109(9):2863–2872.
   PubMed Web of Science ®Google Scholar